DGX:NYE-Quest Diagnostics Incorporated (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 173.34

Change

+1.34 (+0.78)%

Market Cap

USD 11.95B

Volume

1.61M

Analyst Target

USD 138.69
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Quest Diagnostics Inc is the provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

N/A

USD 140.35B
A Agilent Technologies Inc

N/A

USD 32.44B
IQV IQVIA Holdings Inc

N/A

USD 24.71B
LH Laboratory Corporation of Amer..

N/A

USD 20.88B
QGEN Qiagen NV

N/A

USD 9.05B
CRL Charles River Laboratories

N/A

USD 6.92B
ENZ Enzo Biochem Inc

N/A

USD 0.02B
TMO Thermo Fisher Scientific Inc

N/A

N/A
WAT Waters Corporation

N/A

N/A
MTD Mettler-Toledo International I..

N/A

N/A

ETFs Containing DGX

EDOC:LSE Global X Telemedicine & D.. 4.68 % 0.00 %

N/A

USD 4.27M
EDOG:LSE Global X Telemedicine & D.. 4.68 % 0.00 %

N/A

USD 0.30M
EDOC:SW Global X Telemedicine & D.. 4.04 % 0.00 %

N/A

N/A
OWLU:LSE 2.44 % 0.00 %

N/A

N/A
RYH 0.00 % 0.40 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
SMIG ETF Series Solutions - AA.. 0.00 % 0.00 %

N/A

USD 1.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.90% 100% F 89% A-
Dividend Return 1.03% 75% C 43% F
Total Return 15.93% 100% F 89% A-
Trailing 12 Months  
Capital Gain 22.10% 92% A 87% B+
Dividend Return 2.15% 75% C 41% F
Total Return 24.24% 92% A 87% B+
Trailing 5 Years  
Capital Gain 46.55% 82% B 59% D-
Dividend Return 11.92% 100% F 32% F
Total Return 58.47% 82% B 55% F
Average Annual (5 Year Horizon)  
Capital Gain 4.45% 54% F 56% F
Dividend Return 6.38% 54% F 54% F
Total Return 1.93% 88% B+ 44% F
Risk Return Profile  
Volatility (Standard Deviation) 20.24% 69% C- 48% F
Risk Adjusted Return 31.51% 77% C+ 50% F
Market Capitalization 11.95B 50% F 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.60 88% 35%
Price/Book Ratio 2.73 38% 32%
Price / Cash Flow Ratio 14.33 38% 27%
Price/Free Cash Flow Ratio 12.98 75% 36%
Management Effectiveness  
Return on Equity 13.95% 78% 74%
Return on Invested Capital 8.83% 78% 62%
Return on Assets 6.13% 89% 81%
Debt to Equity Ratio 82.84% 22% 41%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.